<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36359827</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>21</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>31</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>The Potential Role of Cytotoxic Immune Effectors in Induction, Progression and Pathogenesis of Amyotrophic Lateral Sclerosis (ALS).</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">3431</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells11213431</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is an auto-immune neurodegenerative disorder affecting the motor-neuron system. The causes of ALS are heterogeneous, and are only partially understood. We studied different aspects of immune pathogenesis in ALS and found several basic mechanisms which are potentially involved in the disease. Our findings demonstrated that ALS patients' peripheral blood contains higher proportions of NK and B cells in comparison to healthy individuals. Significantly increased IFN-&#x3b3; secretion by anti-CD3/28 mAbs-treated peripheral blood mononuclear cells (PBMCs) were observed in ALS patients, suggesting that hyper-responsiveness of T cell compartment could be a potential mechanism for ALS progression. In addition, elevated granzyme B and perforin secretion at a single cell level, and increased cytotoxicity and secretion of IFN-&#x3b3; by patients' NK cells under specific treatment conditions were also observed. Increased IFN-&#x3b3; secretion by ALS patients' CD8+ T cells in the absence of IFN-&#x3b3; receptor expression, and increased CD8+ T cell effector/memory phenotype as well as increased granzyme B at the single cell level points to the CD8+ T cells as potential cells in targeting motor neurons. Along with the hyper-responsiveness of cytotoxic immune cells, significantly higher levels of inflammatory cytokines including IFN-&#x3b3; was observed in peripheral blood-derived serum of ALS patients. Supernatants obtained from ALS patients' CD8+ T cells induced augmented cell death and differentiation of the epithelial cells. Weekly N-acetyl cysteine (NAC) infusion in patients decreased the levels of many inflammatory cytokines in peripheral blood of ALS patient except IFN-&#x3b3;, TNF-&#x3b1;, IL-17a and GMCSF which remained elevated. Findings of this study indicated that CD8+ T cells and NK cells are likely culprits in targeting motor neurons and therefore, strategies should be designed to decrease their function, and eliminate the aggressive nature of these cells. Analysis of genetic mutations in ALS patient in comparison to identical twin revealed a number of differences and similarities which may be important in the pathogenesis of the disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kaur</LastName><ForeName>Kawaljit</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Oral Biology and Medicine, The Jane and Jerry Weintraub Center for Reconstructive Biotechnology, University of California School of Dentistry, 10833 Le Conte Ave, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Po-Chun</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Division of Oral Biology and Medicine, The Jane and Jerry Weintraub Center for Reconstructive Biotechnology, University of California School of Dentistry, 10833 Le Conte Ave, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>Meng-Wei</ForeName><Initials>MW</Initials><Identifier Source="ORCID">0000-0003-3708-5362</Identifier><AffiliationInfo><Affiliation>Division of Oral Biology and Medicine, The Jane and Jerry Weintraub Center for Reconstructive Biotechnology, University of California School of Dentistry, 10833 Le Conte Ave, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mei</LastName><ForeName>Ao</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chovatiya</LastName><ForeName>Nishant</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Oral Biology and Medicine, The Jane and Jerry Weintraub Center for Reconstructive Biotechnology, University of California School of Dentistry, 10833 Le Conte Ave, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huerta-Yepez</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Oral Biology and Medicine, The Jane and Jerry Weintraub Center for Reconstructive Biotechnology, University of California School of Dentistry, 10833 Le Conte Ave, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ni</LastName><ForeName>Weiming</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>IsoPlexis, 35 North East Industrial Road, Branford, CT 06405, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mackay</LastName><ForeName>Sean</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>IsoPlexis, 35 North East Industrial Road, Branford, CT 06405, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>IsoPlexis, 35 North East Industrial Road, Branford, CT 06405, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maharaj</LastName><ForeName>Dipanarine</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>South Florida Bone Marrow Stem Cell Transplant Institute, DBA Maharaj Institute of Immune Regenerative Medicine, 10301 Hagen Ranch Rd Ste. 600, Boynton Beach, FL 33437, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malarkannan</LastName><ForeName>Subramaniam</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-7511-2731</Identifier><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Molecular Immunology and Immunotherapy, Blood Research Institute, Versiti, Milwaukee, WI 53226, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jewett</LastName><ForeName>Anahid</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Oral Biology and Medicine, The Jane and Jerry Weintraub Center for Reconstructive Biotechnology, University of California School of Dentistry, 10833 Le Conte Ave, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Jonsson Comprehensive Cancer Center, UCLA School of Dentistry and Medicine, 10833 Le Conte Ave., Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="D053804">Granzymes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018414" MajorTopicYN="Y">CD8-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053804" MajorTopicYN="N">Granzymes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013602" MajorTopicYN="Y">T-Lymphocytes, Cytotoxic</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CD8+ T cells</Keyword><Keyword MajorTopicYN="N">IFN-&#x3b3;</Keyword><Keyword MajorTopicYN="N">NAC</Keyword><Keyword MajorTopicYN="N">NK cells</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">cytotoxicity</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. W.N., Sean Mackay and J.Z. are employed by and have equity ownership in IsoPlexis.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>10</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>11</Day><Hour>1</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36359827</ArticleId><ArticleId IdType="pmc">PMC9656116</ArticleId><ArticleId IdType="doi">10.3390/cells11213431</ArticleId><ArticleId IdType="pii">cells11213431</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardiman O., Al-Chalabi A., Chio A., Corr E.M., Logroscino G., Robberecht W., Shaw P.J., Simmons Z., van den Berg L.H. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Primers. 2017;3:17085. doi: 10.1038/nrdp.2017.85.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.85</ArticleId><ArticleId IdType="pubmed">29052611</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown R.H., Al-Chalabi A. Amyotrophic Lateral Sclerosis. N. Engl. J. Med. 2017;377:162&#x2013;172. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es M.A., Hardiman O., Chio A., Al-Chalabi A., Pasterkamp R.J., Veldink J.H., van den Berg L.H. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084&#x2013;2098. doi: 10.1016/S0140-6736(17)31287-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Masrori P., Van Damme P. Amyotrophic lateral sclerosis: A clinical review. Eur. J. Neurol. 2020;27:1918&#x2013;1929. doi: 10.1111/ene.14393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14393</ArticleId><ArticleId IdType="pmc">PMC7540334</ArticleId><ArticleId IdType="pubmed">32526057</ArticleId></ArticleIdList></Reference><Reference><Citation>Fecto F., Yan J., Vemula S.P., Liu E., Yang Y., Chen W., Zheng J.G., Shi Y., Siddique N., Arrat H., et al. SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch. Neurol. 2011;68:1440&#x2013;1446. doi: 10.1001/archneurol.2011.250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2011.250</ArticleId><ArticleId IdType="pubmed">22084127</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad A., Bharathi V., Sivalingam V., Girdhar A., Patel B.K. Molecular Mechanisms of TDP-43 Misfolding and Pathology in Amyotrophic Lateral Sclerosis. Front. Mol. Neurosci. 2019;12:25. doi: 10.3389/fnmol.2019.00025.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2019.00025</ArticleId><ArticleId IdType="pmc">PMC6382748</ArticleId><ArticleId IdType="pubmed">30837838</ArticleId></ArticleIdList></Reference><Reference><Citation>Suk T.R., Rousseaux M.W.C. The role of TDP-43 mislocalization in amyotrophic lateral sclerosis. Mol. Neurodegener. 2020;15:45. doi: 10.1186/s13024-020-00397-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-00397-1</ArticleId><ArticleId IdType="pmc">PMC7429473</ArticleId><ArticleId IdType="pubmed">32799899</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock B.J., Bender D.E., Segal B.M., Feldman E.L. The dual roles of immunity in ALS: Injury overrides protection. Neurobiol. Dis. 2015;77:1&#x2013;12. doi: 10.1016/j.nbd.2015.02.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2015.02.017</ArticleId><ArticleId IdType="pubmed">25726748</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W., Beers D.R., Appel S.H. Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis. J. Neuroimmune Pharmacol. 2013;8:888&#x2013;899. doi: 10.1007/s11481-013-9489-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-013-9489-x</ArticleId><ArticleId IdType="pmc">PMC4126425</ArticleId><ArticleId IdType="pubmed">23881705</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers D.R., Henkel J.S., Zhao W., Wang J., Appel S.H. CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc. Natl. Acad. Sci. USA. 2008;105:15558&#x2013;15563. doi: 10.1073/pnas.0807419105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0807419105</ArticleId><ArticleId IdType="pmc">PMC2547419</ArticleId><ArticleId IdType="pubmed">18809917</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O., Siddiqui S., Gabriely G., Lanser A.J., Dake B., Murugaiyan G., Doykan C.E., Wu P.M., Gali R.R., Iyer L.K., et al. Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J. Clin. Investig. 2012;122:3063&#x2013;3087. doi: 10.1172/JCI62636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI62636</ArticleId><ArticleId IdType="pmc">PMC3428086</ArticleId><ArticleId IdType="pubmed">22863620</ArticleId></ArticleIdList></Reference><Reference><Citation>Coque E., Salsac C., Espinosa-Carrasco G., Varga B., Degauque N., Cadoux M., Crab&#xe9; R., Virenque A., Soulard C., Fierle J.K., et al. Cytotoxic CD8(+) T lymphocytes expressing ALS-causing SOD1 mutant selectively trigger death of spinal motoneurons. Proc. Natl. Acad. Sci. USA. 2019;116:2312&#x2013;2317. doi: 10.1073/pnas.1815961116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1815961116</ArticleId><ArticleId IdType="pmc">PMC6369778</ArticleId><ArticleId IdType="pubmed">30674678</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock B.J., Zhou T., Kashlan S.R., Little R.J., Goutman S.A., Feldman E.L. Correlation of Peripheral Immunity with Rapid Amyotrophic Lateral Sclerosis Progression. JAMA Neurol. 2017;74:1446&#x2013;1454. doi: 10.1001/jamaneurol.2017.2255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.2255</ArticleId><ArticleId IdType="pmc">PMC5822195</ArticleId><ArticleId IdType="pubmed">28973548</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock B.J., Famie J.P., Piecuch C.E., Raue K.D., Mendelson F.E., Pieroni C.H., Iniguez S.D., Zhao L., Goutman S.A., Feldman E.L. NK cells associate with ALS in a sex- and age-dependent manner. JCI Insight. 2021;6:e147129. doi: 10.1172/jci.insight.147129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.147129</ArticleId><ArticleId IdType="pmc">PMC8262328</ArticleId><ArticleId IdType="pubmed">33974561</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyce P.I., McGoldrick P., Saccon R.A., Weber W., Fratta P., West S.J., Zhu N., Carter S., Phatak V., Stewart M., et al. A novel SOD1-ALS mutation separates central and peripheral effects of mutant SOD1 toxicity. Hum. Mol. Genet. 2015;24:1883&#x2013;1897. doi: 10.1093/hmg/ddu605.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu605</ArticleId><ArticleId IdType="pmc">PMC4355022</ArticleId><ArticleId IdType="pubmed">25468678</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim G., Gautier O., Tassoni-Tsuchida E., Ma X.R., Gitler A.D. ALS Genetics: Gains, Losses, and Implications for Future Therapies. Neuron. 2020;108:822&#x2013;842. doi: 10.1016/j.neuron.2020.08.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2020.08.022</ArticleId><ArticleId IdType="pmc">PMC7736125</ArticleId><ArticleId IdType="pubmed">32931756</ArticleId></ArticleIdList></Reference><Reference><Citation>Schweikl H., Hartmann A., Hiller K.A., Spagnuolo G., Bolay C., Brockhoff G., Schmalz G. Inhibition of TEGDMA and HEMA-induced genotoxicity and cell cycle arrest by N-acetylcysteine. Dent. Mater. Off. Publ. Acad. Dent. Mater. 2007;23:688&#x2013;695. doi: 10.1016/j.dental.2006.06.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dental.2006.06.021</ArticleId><ArticleId IdType="pubmed">16890983</ArticleId></ArticleIdList></Reference><Reference><Citation>Mokhtari V., Afsharian P., Shahhoseini M., Kalantar S.M., Moini A. A Review on Various Uses of N-Acetyl Cysteine. Cell J. 2017;19:11&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5241507</ArticleId><ArticleId IdType="pubmed">28367412</ArticleId></ArticleIdList></Reference><Reference><Citation>Parasassi T., Brunelli R., Krasnowska E.K., Lundeberg T., Pittaluga E., Romano M.C. Into the redox control: N-acetyl-cysteine pleiotropic effects from the laboratory to clinical applications. Acupunct. Relat. Ther. 2014;2:2&#x2013;13. doi: 10.1016/j.arthe.2013.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arthe.2013.11.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Beg A.A., Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science. 1996;274:782&#x2013;784. doi: 10.1126/science.274.5288.782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.274.5288.782</ArticleId><ArticleId IdType="pubmed">8864118</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Antwerp D.J., Martin S.J., Kafri T., Green D.R., Verma I.M. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science. 1996;274:787&#x2013;789. doi: 10.1126/science.274.5288.787.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.274.5288.787</ArticleId><ArticleId IdType="pubmed">8864120</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng H.C., Arasteh A., Paranjpe A., Teruel A., Yang W., Behel A., Alva J.A., Walter G., Head C., Ishikawa T.O., et al. Increased lysis of stem cells but not their differentiated cells by natural killer cells; de-differentiation or reprogramming activates NK cells. PLoS ONE. 2010;5:e11590. doi: 10.1371/journal.pone.0011590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0011590</ArticleId><ArticleId IdType="pmc">PMC2905395</ArticleId><ArticleId IdType="pubmed">20661281</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng H.C., Bui V., Man Y.G., Cacalano N., Jewett A. Induction of Split Anergy Conditions Natural Killer Cells to Promote Differentiation of Stem Cells through Cell-Cell Contact and Secreted Factors. Front. Immunol. 2014;5:269. doi: 10.3389/fimmu.2014.00269.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2014.00269</ArticleId><ArticleId IdType="pmc">PMC4062968</ArticleId><ArticleId IdType="pubmed">24995006</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng H.C., Inagaki A., Bui V.T., Cacalano N., Kasahara N., Man Y.G., Jewett A. Differential Targeting of Stem Cells and Differentiated Glioblastomas by NK Cells. J. Cancer. 2015;6:866&#x2013;876. doi: 10.7150/jca.11527.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/jca.11527</ArticleId><ArticleId IdType="pmc">PMC4532984</ArticleId><ArticleId IdType="pubmed">26284138</ArticleId></ArticleIdList></Reference><Reference><Citation>Bui V.T., Tseng H.-C., Maung P.O., Kozlowska A., Mann K., Topchyan P., Jewett A. Augmented IFN-&#x3b3; and TNF-&#x3b1; Induced by Probiotic Bacteria in NK Cells Mediate Differentiation of Stem-Like Tumors Leading to Inhibition of Tumor Growth and Reduction in Inflammatory Cytokine Release; Regulation by IL-10. Front. Immunol. 2015;6:576. doi: 10.3389/fimmu.2015.00576.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2015.00576</ArticleId><ArticleId IdType="pmc">PMC4667036</ArticleId><ArticleId IdType="pubmed">26697005</ArticleId></ArticleIdList></Reference><Reference><Citation>Jewett A., Bonavida B. Target-induced inactivation and cell death by apoptosis in a subset of human NK cells. J. Immunol. 1996;156:907&#x2013;915.</Citation><ArticleIdList><ArticleId IdType="pubmed">8558016</ArticleId></ArticleIdList></Reference><Reference><Citation>Jewett A., Cavalcanti M., Bonavida B. Pivotal role of endogenous TNF-alpha in the induction of functional inactivation and apoptosis in NK cells. J. Immunol. 1997;159:4815&#x2013;4822.</Citation><ArticleIdList><ArticleId IdType="pubmed">9366406</ArticleId></ArticleIdList></Reference><Reference><Citation>Jewett A., Bonavida B. Interferon-alpha activates cytotoxic function but inhibits interleukin-2-mediated proliferation and tumor necrosis factor-alpha secretion by immature human natural killer cells. J. Clin. Immunol. 1995;15:35&#x2013;44. doi: 10.1007/BF01489488.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01489488</ArticleId><ArticleId IdType="pubmed">7759599</ArticleId></ArticleIdList></Reference><Reference><Citation>Jewett A., Wang M.Y., Teruel A., Poupak Z., Bostanian Z., Park N.H. Cytokine dependent inverse regulation of CD54 (ICAM1) and major histocompatibility complex class I antigens by nuclear factor kappaB in HEp2 tumor cell line: Effect on the function of natural killer cells. Hum. Immunol. 2003;64:505&#x2013;520. doi: 10.1016/S0198-8859(03)00039-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0198-8859(03)00039-9</ArticleId><ArticleId IdType="pubmed">12691701</ArticleId></ArticleIdList></Reference><Reference><Citation>Parisi G., Saco J.D., Salazar F.B., Tsoi J., Krystofinski P., Puig-Saus C., Zhang R., Zhou J., Cheung-Lau G.C., Garcia A.J., et al. Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist. Nat. Commun. 2020;11:660. doi: 10.1038/s41467-019-12901-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-12901-3</ArticleId><ArticleId IdType="pmc">PMC6994533</ArticleId><ArticleId IdType="pubmed">32005809</ArticleId></ArticleIdList></Reference><Reference><Citation>Axelrod M.L., Nixon M.J., Gonzalez-Ericsson P.I., Bergman R.E., Pilkinton M.A., McDonnell W.J., Sanchez V., Opalenik S.R., Loi S., Zhou J., et al. Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer. Clin. Cancer Res. 2020;26:5668&#x2013;5681. doi: 10.1158/1078-0432.CCR-19-3685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-19-3685</ArticleId><ArticleId IdType="pmc">PMC7642197</ArticleId><ArticleId IdType="pubmed">32826327</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J., Zhou J., Ghinnagow R., Seki T., Iketani S., Soulard D., Paczkowski P., Tsuji Y., MacKay S., Cruz L.J., et al. Targeted Co-delivery of Tumor Antigen and alpha-Galactosylceramide to CD141(+) Dendritic Cells Induces a Potent Tumor Antigen-Specific Human CD8(+) T Cell Response in Human Immune System Mice. Front. Immunol. 2020;11:2043. doi: 10.3389/fimmu.2020.02043.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.02043</ArticleId><ArticleId IdType="pmc">PMC7461784</ArticleId><ArticleId IdType="pubmed">32973811</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma C., Cheung A.F., Chodon T., Koya R.C., Wu Z., Ng C., Avramis E., Cochran A.J., Witte O.N., Baltimore D., et al. Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy. Cancer Discov. 2013;3:418&#x2013;429. doi: 10.1158/2159-8290.CD-12-0383.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-12-0383</ArticleId><ArticleId IdType="pmc">PMC3716460</ArticleId><ArticleId IdType="pubmed">23519018</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi J., Paczkowski P., Shen Y.W., Morse K., Flynn B., Kaiser A., Ng C., Gallatin K., Cain T., Fan R., et al. Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL. Blood. 2018;132:804&#x2013;814. doi: 10.1182/blood-2018-01-828343.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2018-01-828343</ArticleId><ArticleId IdType="pmc">PMC6107882</ArticleId><ArticleId IdType="pubmed">29895668</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Y., Xue Q., Eisele M.R., Sulistijo E.S., Brower K., Han L., Amir el A.D., Pe&#x2019;er D., Miller-Jensen K., Fan R. Highly multiplexed profiling of single-cell effector functions reveals deep functional heterogeneity in response to pathogenic ligands. Proc. Natl. Acad. Sci. USA. 2015;112:E607&#x2013;E615. doi: 10.1073/pnas.1416756112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1416756112</ArticleId><ArticleId IdType="pmc">PMC4343126</ArticleId><ArticleId IdType="pubmed">25646488</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacoangeli A., Initiative A.D.N., Al Khleifat A., Jones A.R., Sproviero W., Shatunov A., Opie-Martin S., Morrison K.E., Shaw P., Shaw C.E., et al. C9orf72 intermediate expansions of 24&#x2013;30 repeats are associated with ALS. Acta Neuropathol. Commun. 2019;7:1&#x2013;7. doi: 10.1186/s40478-019-0724-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-019-0724-4</ArticleId><ArticleId IdType="pmc">PMC6637621</ArticleId><ArticleId IdType="pubmed">31315673</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur K., Cook J., Park S.H., Topchyan P., Kozlowska A., Ohanian N., Fang C., Nishimura I., Jewett A. Novel Strategy to Expand Super-Charged NK Cells with Significant Potential to Lyse and Differentiate Cancer Stem Cells: Differences in NK Expansion and Function between Healthy and Cancer Patients. Front. Immunol. 2017;8:297. doi: 10.3389/fimmu.2017.00297.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.00297</ArticleId><ArticleId IdType="pmc">PMC5380683</ArticleId><ArticleId IdType="pubmed">28424683</ArticleId></ArticleIdList></Reference><Reference><Citation>Jewett A., Kos J., Kaur K., Turnsek T.L., Breznik B., Senjor E., Wong P., Nguyen K.Y., Ko M.W. Multiple Defects of Natural Killer Cells in Cancer Patients: Anarchy, Dysregulated Systemic Immunity, and Immunosuppression in Metastatic Cancer. Crit. Rev. Immunol. 2020;40:93&#x2013;133. doi: 10.1615/CritRevImmunol.2020033391.</Citation><ArticleIdList><ArticleId IdType="doi">10.1615/CritRevImmunol.2020033391</ArticleId><ArticleId IdType="pubmed">32749091</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng H.C., Arasteh A., Kaur K., Kozlowska A., Topchyan P., Jewett A. Differential Cytotoxicity but Augmented IFN-gamma Secretion by NK Cells after Interaction with Monocytes from Humans, and Those from Wild Type and Myeloid-Specific COX-2 Knockout Mice. Front. Immunol. 2015;6:259. doi: 10.3389/fimmu.2015.00259.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2015.00259</ArticleId><ArticleId IdType="pmc">PMC4460808</ArticleId><ArticleId IdType="pubmed">26106386</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacalano N.A., Le D., Paranjpe A., Wang M.Y., Fernandez A., Evazyan T., Park N.H., Jewett A. Regulation of IGFBP6 gene and protein is mediated by the inverse expression and function of c-jun N-terminal kinase (JNK) and NFkappaB in a model of oral tumor cells. Apoptosis. 2008;13:1439&#x2013;1449. doi: 10.1007/s10495-008-0270-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10495-008-0270-1</ArticleId><ArticleId IdType="pubmed">18982452</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu X.Y. STAT3 in immune responses and inflammatory bowel diseases. Cell Res. 2006;16:214&#x2013;219. doi: 10.1038/sj.cr.7310029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.cr.7310029</ArticleId><ArticleId IdType="pubmed">16474436</ArticleId></ArticleIdList></Reference><Reference><Citation>Jewett A., Cacalano N.A., Teruel A., Romero M., Rashedi M., Wang M., Nakamura H. Inhibition of nuclear factor kappa B (NFkappaB) activity in oral tumor cells prevents depletion of NK cells and increases their functional activation. Cancer Immunol. Immunother. 2006;55:1052&#x2013;1063. doi: 10.1007/s00262-005-0093-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00262-005-0093-7</ArticleId><ArticleId IdType="pubmed">16328384</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozlowska A.K., Topchyan P., Kaur K., Tseng H.C., Teruel A., Hiraga T., Jewett A. Differentiation by NK cells is a prerequisite for effective targeting of cancer stem cells/poorly differentiated tumors by chemopreventive and chemotherapeutic drugs. J. Cancer. 2017;8:537&#x2013;554. doi: 10.7150/jca.15989.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/jca.15989</ArticleId><ArticleId IdType="pmc">PMC5370498</ArticleId><ArticleId IdType="pubmed">28367234</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobbs K., Tabellini G., Calzoni E., Patrizi O., Martinez P., Giliani S.C., Moratto D., Al-Herz W., Cancrini C., Cowan M., et al. Natural Killer Cells from Patients with Recombinase-Activating Gene and Non-Homologous End Joining Gene Defects Comprise a Higher Frequency of CD56(bright) NKG2A(+++) Cells, and Yet Display Increased Degranulation and Higher Perforin Content. Front. Immunol. 2017;8:798. doi: 10.3389/fimmu.2017.00798.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.00798</ArticleId><ArticleId IdType="pmc">PMC5511964</ArticleId><ArticleId IdType="pubmed">28769923</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur K., Ko M.W., Ohanian N., Cook J., Jewett A. Osteoclast-expanded super-charged NK-cells preferentially select and expand CD8+ T cells. Sci. Rep. 2020;10:20363. doi: 10.1038/s41598-020-76702-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-76702-1</ArticleId><ArticleId IdType="pmc">PMC7683603</ArticleId><ArticleId IdType="pubmed">33230147</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen D., Zhao Y., Feng Y., Jin C., Yang Q., Qiu H., Xie H., Xie S., Zhou Y., Huang J. Expression of TLR2, TLR3, TLR4, and TLR7 on pulmonary lymphocytes of Schistosoma japonicum-infected C57BL/6 mice. Innate Immun. 2019;25:224&#x2013;234. doi: 10.1177/1753425919840424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1753425919840424</ArticleId><ArticleId IdType="pmc">PMC6830883</ArticleId><ArticleId IdType="pubmed">31018808</ArticleId></ArticleIdList></Reference><Reference><Citation>Jewett A., Bonavida B. Pentoxifylline suppresses interleukin-2-mediated activation of immature human natural killer cells by inhibiting endogenous tumor necrosis factor-alpha secretion. J. Clin. Immunol. 1994;14:31&#x2013;38. doi: 10.1007/BF01541173.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01541173</ArticleId><ArticleId IdType="pubmed">8132735</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox M.A., Kahan S.M., Zajac A.J. Anti-viral CD8 T cells and the cytokines that they love. Virology. 2013;435:157&#x2013;169. doi: 10.1016/j.virol.2012.09.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2012.09.012</ArticleId><ArticleId IdType="pmc">PMC3580945</ArticleId><ArticleId IdType="pubmed">23217625</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivashkiv L.B. IFN&#x3b3;: Signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat. Rev. Immunol. 2018;18:545&#x2013;558. doi: 10.1038/s41577-018-0029-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-018-0029-z</ArticleId><ArticleId IdType="pmc">PMC6340644</ArticleId><ArticleId IdType="pubmed">29921905</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank K., Paust S. Dynamic Natural Killer Cell and T Cell Responses to Influenza Infection. Front. Cell. Infect. Microbiol. 2020;10:425. doi: 10.3389/fcimb.2020.00425.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2020.00425</ArticleId><ArticleId IdType="pmc">PMC7461885</ArticleId><ArticleId IdType="pubmed">32974217</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller C.H.T., Maher S.G., Young H.A. Clinical Use of Interferon-gamma. Ann. N. Y. Acad. Sci. 2009;1182:69&#x2013;79. doi: 10.1111/j.1749-6632.2009.05069.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2009.05069.x</ArticleId><ArticleId IdType="pmc">PMC6574079</ArticleId><ArticleId IdType="pubmed">20074276</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro F., Cardoso A.P., Gon&#xe7;alves R.M., Serre K., Oliveira M.J. Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion. Front. Immunol. 2018;9:847. doi: 10.3389/fimmu.2018.00847.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00847</ArticleId><ArticleId IdType="pmc">PMC5945880</ArticleId><ArticleId IdType="pubmed">29780381</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>